Characteristics	Total (N=19)
Median age (range), year	31 (22-45)
Male/female	12 / 7
Mean follow up time(range), month	11.5 (10-19.5)
Underlying diagnosis AML ALL MDS NHL CML	7 (36.84%) 5 (26.32%) 2 (10.53%) 3 (15.79%) 2 (10.53%)
Stem cell source PB PB+BM	13 (68.42%) 6 (31.58%)
The courses of GVHD After HSCT Reduce the dose of FK/CSA Discontinue FK/CSA Others	5 (26.32%) 12 (63.16%) 1 (5.26%) 1 (5.26%)
The grade of GVHD II III IV	12 (63.16%) 4 (21.05%) 3 (15.79%)
Involved organ Skin Liver Gastrointestinal	17 (89.47%) 6 (31.58%) 2 (10.53%)
Number of involved organs 1 2 ≥3	13 (68.42%) 5 (26.32%) 1 (5.26%)